pharma · Schizophrenia · Bipolar I Disorder · LBRX
LB PHARMACEUTICALS
LB PHARMACEUTICALS INC
LB PHARMACEUTICALS is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker LBRX. Primary therapeutic focus areas include Schizophrenia, Bipolar I Disorder. NovaPharmaNews links 3 clinical
New York, USA HQ
2015 Founded
36 Employees
Public company Type
LBRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2015
- Employees
- 36
- Programs
- 3
- Drugs
- 1
- Patents
- 7
LB-102
Phase 2 · small molecule · Bipolar I Disorder
LB-102 for Bipolar I Disorder is a Phase 2 program (small_molecule) at LB PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Internal code LB-102-011
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- LB PHARMACEUTICALS INC
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Bipolar I Disorder
- Status
- active
- Trials
- 1